This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (11)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Glaucoma  • Alert me on articles by topic

Keith Green, PhD, DSc

Arch Ophthalmol. 1998;116:1433-1437.

Objective  To discuss the clinical effects, including toxicological data, of marijuana and its many constituent compounds on the eye and the remainder of the body. A perspective is given on the use of marijuana and the cannabinoids in the treatment of glaucoma.

Results  Although it is undisputed that smoking of marijuana plant material causes a fall in intraocular pressure (IOP) in 60% to 65% of users, continued use at a rate needed to control glaucomatous IOP would lead to substantial systemic toxic effects revealed as pathological changes.

Conclusions  Development of drugs based on the cannabinoid molecule or its agonists for use as topical or oral antiglaucoma medications seems to be worthy of further pursuit. Among the latter chemicals, some have no known adverse psychoactive side effects. Smoking of marijuana plant material for the reduction of elevated IOP in glaucoma is ill-advised, given its toxicological profile.

From the Departments of Ophthalmology, and Physiology and Endocrinology, Medical College of Georgia, Augusta. The author has no commercial or proprietary interest in any drug or product mentioned in this article.

RELATED ARTICLE

Marijuana and Glaucoma
Paul L. Kaufman
Arch Ophthalmol. 1998;116(11):1512-1513.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Marijuana and Glaucoma
Kaufman
Arch Ophthalmol 1998;116:1512-1513.
FULL TEXT